The Roche, Novartis and Kraft Group-backed, protein degradation-focused drug developer received $150m in series B funding and $20m in venture debt.

The move came after the digital health technology provider, which has a raft of corporate investors, reportedly failed to raise a nine-figure round last year.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Endeavor Group is likely to sell shares in the game developer, which is near to raising money in a round that will boost its valuation from $15bn to $17bn.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.

The Relx-backed big data analyser is reportedly lining up a confidential IPO filing in the coming weeks having previously raised $1.9bn in equity funding.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.